Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Short term Debt (2021 - 2024)

Biodesix filings provide 4 years of Short term Debt readings, the most recent being $5.8 million for Q2 2024.

  • On a quarterly basis, Short term Debt fell 59.91% to $5.8 million in Q2 2024 year-over-year; TTM through Jun 2024 was $5.8 million, a 59.91% decrease, with the full-year FY2023 number at $21.9 million, up 111.36% from a year prior.
  • Short term Debt hit $5.8 million in Q2 2024 for Biodesix, down from $19.2 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $21.9 million in Q4 2023 to a low of $5.8 million in Q2 2024.
  • Median Short term Debt over the past 4 years was $13.1 million (2021), compared with a mean of $13.7 million.
  • Biggest five-year swings in Short term Debt: soared 111.36% in 2023 and later crashed 59.91% in 2024.
  • Biodesix's Short term Debt stood at $17.8 million in 2021, then tumbled by 41.79% to $10.3 million in 2022, then soared by 111.36% to $21.9 million in 2023, then crashed by 73.29% to $5.8 million in 2024.
  • The last three reported values for Short term Debt were $5.8 million (Q2 2024), $19.2 million (Q1 2024), and $21.9 million (Q4 2023) per Business Quant data.